Autopsy report · NCT05099536

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

“Company's decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

3D Medicines (Beijing) Co., Ltd.

Sponsor type

Industry

Conditions

Solid Tumor, Adult

Interventions

3D011-08

Participants

0

Sites

1

Countries

China

Trials that died the same way

• A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
  “Company decision” (97% match in meaning)
• Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
  “Company business decision” (89% match in meaning)
• A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
  “Corporate decision” (88% match in meaning)
• HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
  “Business decision” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.